Shoulder Innovations opened lower at $21.50, compared with its previous close of $21.92. In the last trading session, the stock traded between $20.76 and $21.59. It showed a downward intraday trend.
An investment of $100 made 2 years ago in Shoulder Innovations is now worth
$ 140.01
Giving a profit of
$ 40.01 (40.01%)
Note: Past profits do not guarantee future returns.
Rating from 2 Analysts
Today's Change
$-0.85 (-3.87%)
Day High
$21.59
Day Low
$20.76
Day Open
$21.50
Prev Close
$21.92
Volume
80,024
1W Return
0.23%
1M Return
15.40%
3M Return
7.37%
6M Return
59.39%
1Y Return
85.49%
Market Cap ($ Mn)
441
PE Ratio
26.12
PB Ratio
3.54
PEG Ratio
-
ROE
-209.39%
ROCE
-42.88%
EPS (TTM)
-
1 Week
0.23%
1 Month
15.40%
3 Months
7.37%
6 Months
59.39%
9 Months
72.02%
Shoulder Innovations Q3FY26 Results: Revenue up 38% to $16.2 million
Net revenue rose 38% YoY to $16.2 million in Q3FY26. Gross margin improved to 78.5% from 76.2% in the prior year. Implant volumes grew 34% YoY to 2,126 units. Full-year FY26 revenue guidance raised to $68-$70 million. Cash position stands at $92.3 million with improved cash burn.
7 days agoShoulder Innovations gets FDA clearance for N-22 humeral head
Shoulder Innovations (NYSE: SI) received FDA 510(k) clearance for the N-22 Humeral Head. The titanium implant targets patients with metal hypersensitivity. The company announced the full commercial launch of the product.
2mo agoShoulder Innovations signs exclusive US deal with ALM Ortho for bespoke implants
Shoulder Innovations signs exclusive US deal with ALM Ortho for bespoke titanium implants. Partnership targets severe shoulder deformities and complex revision cases with no current solutions. ALM Ortho handles design and manufacturing; Shoulder Innovations manages sales and case identification. CEO Rob Ball says deal addresses unmet need and bolsters company's shoulder surgical care offerings. Specific financial terms of the agreement remain confidential.
2mo agoShoulder Innovations settles patent litigation with Catalyst OrthoScience
Shoulder Innovations enters settlement with Catalyst OrthoScience. Agreement resolves all outstanding patent litigation between firms. Specific terms of the settlement remain confidential. Company focuses exclusively on shoulder surgical care market.
2mo agoUBS raises Shoulder Innovations price target to $28 on Buy
UBS analyst Patrick Wood maintains a Buy rating on Shoulder Innovations (NYSE: SI) and raises the price target from $27 to $28. This adjustment reflects sustained confidence in the company's orthopedic device portfolio and growth prospects, offering investors a slightly higher valuation benchmark.
3mo agoShoulder Innovations files $300M shelf for mixed securities
Shoulder Innovations Inc. files a $300M shelf registration for various securities including stocks, debt, and warrants. The filing also covers the resale of 8,103,026 shares by existing stockholders, from which the company receives no proceeds.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $343.39 | +0.39% | $9,11,909.92M | 15.32 | |
| $50.67 | -0.02% | $3,49,633.59M | 14.39 | |
| $90.20 | +0.36% | $3,09,034.94M | 14.79 | |
| $203.54 | +0.55% | $2,82,875.21M | 17.85 | |
| $21.94 | +1.34% | $2,60,377.56M | 14.95 | |
| $85.80 | +0.05% | $2,57,558.73M | 12.60 | |
| $124.28 | +0.33% | $2,09,970.56M | 17.99 | |
| $124.21 | +1.59% | $2,05,593.01M | 14.35 | |
| $12.48 | -0.64% | $1,81,664.87M | 14.26 | |
| $24.75 | +1.77% | $1,56,796.41M | 14.96 | |
| $49.38 | +0.43% | $1,52,668.10M | 18.67 | |
| $26.21 | -1.06% | $1,44,439.77M | 13.28 |
An investment of $100 made 2 years ago in Shoulder Innovations is now worth
$ 140.01
Giving a profit of
$ 40.01 (40.01%)
Note: Past profits do not guarantee future returns.
